Print this page    •   Back to Web version of article

What's New in Treatment Information?
Excerpts From Hotline Memos of March 2001
from the Information Department of Project Inform

April 2001

Valganciclovir Recommended for Approval

The Antiviral Drugs Advisory Committee to the Food and Drug Administration recommended that valganciclovir be approved for treating active CMV retinitis and maintenance therapy (to prevent relapse of CMV). Valganciclovir is an improved oral formulation of ganciclovir. Clinical studies show that valganciclovir is as effective as the intravenous (injection into the vein) form of the drug, which is commonly used to treat CMV disease.

The dose used to treat CMV retinitis was 900mg twice a day for the first 21 days and then 900mg once a day for the next seven days. However, maintenance therapy usually requires the drug to be given lifelong. Valganciclovir is expected to be available in pharmacies in May 2001. In the meantime, an expanded access program is open for early access to the drug. Call Project Inform's Hotline toll-free at 1-800-822-7422 for a list of participating sites.


Back to the What's New? April 2001 Table of Contents.




This article was provided by Project Inform. It is a part of the publication What's New. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art5247.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.